U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Top Cited Papers
- 29 July 2016
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in MMWR. Recommendations and Reports
- Vol. 65 (3), 1-103
- https://doi.org/10.15585/mmwr.rr6503a1
Abstract
The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (US. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, duringAugust 26-28, 2015. The information in this report updates the 2010 U.S. MEC (CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR 2010:59 [No. RR-4]). Notable updates include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breaseeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. The recommendations in this report are intended to assist health care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.This publication has 228 references indexed in Scilit:
- Feasibility of postpartum placement of the levonorgestrel intrauterine system more than 6 h after vaginal birthContraception, 2012
- Combined Oral Contraceptives and Antiretroviral PK/PD in Malawian Women: Pharmacokinetics and Pharmacodynamics of a Combined Oral Contraceptive and a Generic Combined Formulation Antiretroviral in MalawiJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Early Weight Gain Related to Later Weight Gain in Adolescents on Depot Medroxyprogesterone AcetateObstetrics & Gynecology, 2011
- Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy womenBritish Journal of Clinical Pharmacology, 2011
- Postplacental or Delayed Insertion of the Levonorgestrel Intrauterine Device After Vaginal DeliveryObstetrics & Gynecology, 2010
- Migraine Headache and Ischemic Stroke Risk: An Updated Meta-analysisThe American Journal of Medicine, 2010
- Obesity and oral contraceptive pill failureContraception, 2009
- Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive useAmerican Journal of Obstetrics and Gynecology, 2009
- Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective studyFertility and Sterility, 2008
- Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093Contraception, 2008